TOKYO, Japan I December 18, 2020 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the achievement of the primary endpoint of phase 3 study (hereinafter, Study) mirogabalin for central neuropathic pain after spinal cord injury.
The Study was conducted in Asia (Japan, South Korea, and Taiwan) in a double-blinded manner to evaluate the efficacy and safety of mirogabalin in comparison with the placebo in 274 patients with central neuropathic pain after spinal cord injury.
Results of the primary endpoint in the Study, the change in the average daily pain score, from baseline to Week 14 with placebo, show superiority of mirogabalin over the placebo, achieving the primary objective. Furthermore, no additional safety concerns were observed.
The detailed results of the Study will be presented at academic conferences and in publications.
Daiichi Sankyo will continue efforts to provide new treatment options for diverse patients suffering from pain.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit:www.daiichisankyo.com.
SOURCE: Daiichi Sankyo
Post Views: 247
TOKYO, Japan I December 18, 2020 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the achievement of the primary endpoint of phase 3 study (hereinafter, Study) mirogabalin for central neuropathic pain after spinal cord injury.
The Study was conducted in Asia (Japan, South Korea, and Taiwan) in a double-blinded manner to evaluate the efficacy and safety of mirogabalin in comparison with the placebo in 274 patients with central neuropathic pain after spinal cord injury.
Results of the primary endpoint in the Study, the change in the average daily pain score, from baseline to Week 14 with placebo, show superiority of mirogabalin over the placebo, achieving the primary objective. Furthermore, no additional safety concerns were observed.
The detailed results of the Study will be presented at academic conferences and in publications.
Daiichi Sankyo will continue efforts to provide new treatment options for diverse patients suffering from pain.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit:www.daiichisankyo.com.
SOURCE: Daiichi Sankyo
Post Views: 247
